Last-Resort drug access: asciminib opens for CML patients
NCT ID NCT04360005
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides asciminib (ABL001) to people with chronic phase chronic myeloid leukemia who have no other treatment options and cannot join a clinical trial. It is a managed access program, not a formal study, and aims to offer potential benefit when standard therapies are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- asciminib (ABL001)
- What this could lead to
- If successful, this program could provide a treatment option for people with chronic phase CML who have no other alternatives.
- What could go wrong
- This is an early-access program, not a clinical trial, so data on safety and effectiveness is limited. It is only for patients who cannot join a trial or use other therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.